Amin Haiderali

Statistics

Publications

Citations

545

H-Index

Active since

2009

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Universitätsklinikum Erlangen

Baylor University Medical Center

Texas Oncology

Comprehensive Cancer Center Erlangen

Amin Haiderali is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and triple-negative breast cancer therapy.

ORCID

Publications per year

2009–2024

Publications

Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population

Amin Haiderali, Laura Menditto, Margaret Good et al. · Supportive Care in Cancer · 2010 · 120 citations

Medicine, Oncology, Pharmacoeconomics +13

Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia

Keith Tolley, Catherine Goad, Yunni Yi et al. · The European Journal of Health Economics · 2012 · 91 citations

Pharmacy, Oncology, Cost-utility Analysis +14

Real-World Effectiveness Outcomes in Patients Diagnosed with Metastatic Triple-Negative Breast Cancer

Karen E Skinner, Amin Haiderali, Min Huang et al. · Future Oncology · 2020 · 52 citations

Medicine, Oncology, Breast Oncology +14

Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study

Rebecca Dent, Javier Cortés, Lajos Pusztai et al. · JNCI Journal of the National Cancer Institute · 2024 · 34 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

Min Huang, Peter A. Fasching, Amin Haiderali et al. · Advances in Therapy · 2023 · 31 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17

1–5 of 18